Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Bio-Marker Project
Investigator: Robert J Bloch PhD, Professor of Physiology at the University of Maryland Recent studies from my lab have shown that a protein, called “SLC34A2” (not a name to trip…
Read MoreOptimizing Gapmer Therapy for Facioscapulohumeral Muscular Dystrophy
Principle Investigator: Yi-Wen Chen Research Institution: George Washington School of Medicine Antisense oligonucleotide (AON) therapy is a promising approach to treating FSHD. However, several issues arise with AONs including: difficulty…
Read MoreIn vivo model to validate drugs targeting DUX4 enhancer/promoter activity
Principle Investigator: Yosuke Hiramuki (at Peter Jone’s laboratory) Research Institution: University of Nevada DUX4 is normally expressed in testis in healthy individuals and aberrantly expressed in specific skeletal muscles of…
Read MorePre-clinical testing for FSHD CRISPR-inhibition therapy
Principle Investigator: Associate Professor Peter Jones Research Institution: University of Nevada CRISPR technology provides an avenue for targeting and correcting virtually any sequence in the human genome, with long-term or…
Read MoreFacio Therapies
Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle-toxic DUX4.…
Read MoreDevelopment of next-generation AAV vectors for effective CRISPR inhibition of FSHD
Investigator: Charis L. Himeda, PhD, Research Assistant Professor, University of Nevada, Reno School of Medicine, Reno NV USA CRISPR technology provides an avenue for specifically targeting and manipulating virtually any…
Read More